Joseph Jimenez | |
|---|---|
 Jimenez at the World Economic Forum in 2017 | |
| Nationality | American |
| Alma mater | Stanford University University of California, Berkeley [1] |
| Occupation | Former CEO of Novartis |
Joseph Jimenez is the former CEO of the Swiss pharmaceutical company Novartis. [2]
Jimenez earned a bachelor's degree from Stanford University in 1982, and an MBA from Berkeley's Haas School of Business in 1984. [3]
Jimenez began his career at Clorox before joining ConAgra Foods. [4] [5] [6] Prior to joining Novartis, he was head of H. J. Heinz Company's North American business from 2002 to 2006. He was also a non-executive director of AstraZeneca from 2002 to 2007, as well as an advisor for the Blackstone Group. [5]
Jimenez joined Novartis in 2007 as Division Head of Novartis Pharmaceutical and was named CEO in 2010 [7] by his predecessor and Chairman Daniel Vasella. [8]
During his time at Novartis, Jimenez increasingly applied standard business metrics to pharma cash flow, purchasing and competitive bidding, confident that his experience in consumer goods would help to realize improvements in Novartis' operations. His cost-cutting moves, focused mostly on marketing and administration, came steadily, with more than a billion cut in 2010, and even more than that in 2011. [9]
Jimenez joined the board of directors at General Motors on June 9, 2015 [10] [11]
Jimenez resigned from Novartis, leaving in February 2018, and was succeeded by Vasant Narasimhan. [12] [13]
He joined the Board of Directors of San Francisco biotech startup uBiome in September 2018 and stepped down in April 2019 to start the biotech venture fund Aditum Bio. [14]
Jimenez also has served on the Board of Directors of Procter & Gamble since 2018, where he is lead independent director. [15] He also serves as Chairman of Century Therapeutics, an iPSC derived allogeneic cell therapy company, and is on the Board of Graphite Bio, a gene therapy company. [16] [17]
Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.
Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. Originally, the corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index.
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
Daniel Lucius Vasella is a Swiss medical doctor, author, and executive who served as CEO and chairman of the Swiss pharmaceutical company Novartis AG, the world's fifth largest drug company. During his tenure Novartis shares fell 10%, compared to the industry average. In February 2013 Vasella was awarded close to $78 million in a "golden handshake"
John Mendlein is a biotech executive who has held leadership positions in biotech companies in Boston, San Diego and Toronto.
Fred Hassan, is a Pakistan-born American business executive who works for Warburg Pincus and was CEO of three global pharmaceutical companies.
Alexion Pharmaceuticals, a subsidiary of AstraZeneca, is a pharmaceutical company headquartered in Boston, Massachusetts that specializes in orphan drugs to treat rare diseases.
Jeremy Levin is a South African-born businessman, medical doctor and research scientist. In 2018, Levin was named as one of the most influential figures in the biopharmaceutical industry.
Arie S. Belldegrun, FACS, is an Israeli-American urologic oncologist, billionaire businessman and investor.
Geoffrey von Maltzahn is an American biological engineer and businessman in the biotechnology and life sciences industry who has founded a number of companies including Indigo Agriculture, Sana Biotechnology, Kaleido Biosciences, Seres Therapeutics, Axcella Health, Generate Biomedicines and Tessera Therapeutics. He has over 200 bioengineering and biotechnology patents and applications.
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.
Flemming Ørnskov is a Danish businessman. He has been the chief executive officer (CEO) of Galderma since October 2019.
Samsung Biologics is a South Korean biotechnology company headquartered in Songdo, Incheon, South Korea. The biotech division of Samsung Group, it provides contract development and manufacturing (CDMO) services to the biopharmaceutical industry.
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Roivant is a healthcare company focused on applying technology to drug development and building subsidiary biotech and healthcare technology companies. It was founded in 2014 by Vivek Ramaswamy.
Vasant "Vas" Narasimhan is an Indian-American physician and the chief executive officer of Novartis. He succeeded Joseph Jimenez who left Novartis in 2018. He worked in McKinsey & Co and Sandoz before joining Novartis.
Jeffrey Leiden is an American businessman who is the executive chairman of Vertex Pharmaceuticals, a biotechnology company based in Boston, Massachusetts. He was initially appointed to the board of directors of the company in 2009 and was CEO and president from February 2012 to March 2020.
John Maraganore is an American scientist, entrepreneur, and life sciences industry leader.
Brent Saunders is an American biopharma executive, entrepreneur, and chief executive officer and chairman of eye health company Bausch & Lomb. He is helped lead various mergers and acquisitions and overseen the mergers between Merck and Schering-Plough, the acquisition of Bausch + Lomb by Valeant Pharmaceuticals, and the $63 billion acquisition of Allergan by Abbvie. He is the founder of special-purpose acquisition company (SPAC) Vesper Healthcare Acquisition. Saunders is also executive chairman of medical aesthetics companies The Beauty Health Company and Hugel America.